Telomir Pharmaceuticals Reveals Promising In Vitro Data on Telomir-1

Telomir Pharmaceuticals, a preclinical-stage biotech firm, announced new in vitro data highlighting Telomir-1's potential as a first-in-class epigenetic therapy. Studies reveal that Telomir-1 effectively inhibits UTX (KDM6A), an enzyme linked to abnormal DNA methylation patterns commonly seen in cancer and aging. This inhibition could reset faulty gene programming, impacting cancer treatment, autoimmune diseases, and neurodegeneration.

These findings suggest Telomir-1 might counteract age-related epigenetic drift and reawaken tumor suppressor genes. Notably, Telomir-1 showed no activity against GCN5L2, reducing concerns about toxicity and enhancing its safety profile. Telomir-1 also demonstrated low-level activity against Tankyrases, part of the Wnt/β-catenin pathway, crucial for cancer growth control.